Technical due diligence and defensibility assessment of AI and machine-learning products: whether the model does what the deck says, whether the moat survives the next generation of foundation models, and whether the data advantage compounds or evaporates. The findings come back in the documents deal teams already use, which is a red flag report when you need a fast go/no-go and a full DD memo once the deal advances.
Where a claim needs testing rather than reading, Datatroph builds the evaluation harness, and it stays with you after the engagement.
Datatroph has been moving data and making it useful since 2008, across a wide range of industries. The AI work is recent and now accounts for nearly all of it, with a good deal on clinical and genetic data. Recent engagements include cancer-detection and therapy-target products, clinical scribing companies, AI products with no connection to medicine, and the buy side itself as a Venture Partner.
Brian Hur, who runs Datatroph, co-founded VetPronto and ran it as CEO through YC W15, and carried the P&L as CIO of a veterinary group in Australia; both companies and how they ended are in the record below.
